Trauma to the Skin, Subcutaneous Tissue and Breast DRG Reimbursement

DRG 605 addresses inpatient stays for trauma to the skin, subcutaneous tissue, and breast without Major Complication or Comorbidity, encompassing procedures such as wound debridement and soft tissue repair. Correct assignment impacts Medicare inpatient reimbursement by aligning payment with expected resource use for lower-severity trauma cases.

DRG 605 Overview

DRG 605 covers inpatient admissions for treatment of trauma to the skin, subcutaneous tissue, and breast without Major Complication or Comorbidity. Typical cases include debridement, wound repair, and management of soft tissue injuries that do not carry higher-severity comorbid conditions. This Diagnosis-Related Group is important for Medicare payment because it groups similar resource use and sets the base inpatient reimbursement for these lower-severity trauma encounters. Accurate coding and documentation of the absence of Major Complication or Comorbidity determine assignment to this Diagnosis-Related Group and affect payment levels.

Acute wound management and hemostasis trials evaluating early interventions for traumatic skin and subcutaneous injuries: randomized or pragmatic trials test rapid hemostatic agents, topical dressings, negative-pressure wound therapy, or procedural techniques applied in the emergency or operating room setting for patients with lacerations, degloving injuries, or blunt/penetrating soft-tissue trauma. These studies enroll primarily adult trauma patients admitted for operative or bedside wound management and measure short-term endpoints such as time to hemostasis, infection rates, need for reoperation, transfusion requirement, and length of stay. Evidence from this research informs hospital resource use, procedural coding and reimbursement under the DRG by potentially reducing complications and LOS, which are key drivers of cost for payers and providers.
Comparative effectiveness studies of closure methods and reconstructive approaches for complex soft-tissue and breast trauma: observational cohorts or randomized studies compare primary closure, skin grafts, local flaps, and staged reconstructive strategies in patients with varying wound sizes, contamination levels, and comorbidities (e.g., diabetes, peripheral vascular disease). These trials focus on functional and cosmetic outcomes, wound healing time, readmission rates, and downstream need for secondary procedures over weeks to months. For clinicians and payers, such research helps determine which approaches yield the best balance of clinical outcomes and downstream costs, guiding surgical decision-making and appropriate DRG resource allocation.
Post-discharge outcomes and care-pathway studies examining infection prevention, rehabilitation, and utilization after inpatient treatment for skin/subcutaneous trauma: prospective cohort studies and quality-improvement trials evaluate discharge protocols, outpatient wound clinic follow-up timing, home health needs, antibiotic stewardship, and rates of emergency revisits or readmission in the 30–90 day window. These studies typically enroll patients transitioning from inpatient care who have risk factors for poor healing (obesity, smoking, immunosuppression) and assess metrics relevant to readmission, prolonged antibiotic use, and overall episode-of-care costs. Results are directly relevant to payers and hospitals aiming to reduce readmissions and total cost of care associated with this DRG by optimizing post-discharge care pathways and bundling strategies.

Acute wound management and hemostasis trials evaluating early interventions for traumatic skin and subcutaneous injuries: randomized or pragmatic trials test rapid hemostatic agents, topical dressings, negative-pressure wound therapy, or procedural techniques applied in the emergency or operating room setting for patients with lacerations, degloving injuries, or blunt/penetrating soft-tissue trauma. These studies enroll primarily adult trauma patients admitted for operative or bedside wound management and measure short-term endpoints such as time to hemostasis, infection rates, need for reoperation, transfusion requirement, and length of stay. Evidence from this research informs hospital resource use, procedural coding and reimbursement under the DRG by potentially reducing complications and LOS, which are key drivers of cost for payers and providers.
Comparative effectiveness studies of closure methods and reconstructive approaches for complex soft-tissue and breast trauma: observational cohorts or randomized studies compare primary closure, skin grafts, local flaps, and staged reconstructive strategies in patients with varying wound sizes, contamination levels, and comorbidities (e.g., diabetes, peripheral vascular disease). These trials focus on functional and cosmetic outcomes, wound healing time, readmission rates, and downstream need for secondary procedures over weeks to months. For clinicians and payers, such research helps determine which approaches yield the best balance of clinical outcomes and downstream costs, guiding surgical decision-making and appropriate DRG resource allocation.
Post-discharge outcomes and care-pathway studies examining infection prevention, rehabilitation, and utilization after inpatient treatment for skin/subcutaneous trauma: prospective cohort studies and quality-improvement trials evaluate discharge protocols, outpatient wound clinic follow-up timing, home health needs, antibiotic stewardship, and rates of emergency revisits or readmission in the 30–90 day window. These studies typically enroll patients transitioning from inpatient care who have risk factors for poor healing (obesity, smoking, immunosuppression) and assess metrics relevant to readmission, prolonged antibiotic use, and overall episode-of-care costs. Results are directly relevant to payers and hospitals aiming to reduce readmissions and total cost of care associated with this DRG by optimizing post-discharge care pathways and bundling strategies.

OpenPayer

Summary & Overview

Trauma to the Skin, Subcutaneous Tissue and Breast without MCC: Inpatient Reimbursement Overview

DRG 605 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes